Glucagon-like peptide-1 receptor agonists and aspiration risk: a narrative review
Metabolic indicators that may be associated with reduced GLP-1 activity include: Persistent elevated blood glucose levels , particularly postprandial (after-meal) hyperglycaemia Difficulty achieving or maintaining a healthy weight despite dietary efforts Increased appetite and reduced satiety after meals, leading to frequent snacking Diagnosis of type 2 diabetes or non-diabetic hyperglycaemia (NDH, sometimes called prediabetes), conditions where GLP-1 response is often blunted Features of metabolic syndrome , including central obesity, hypertension, and dyslipidaemia Individuals may also notice practical symptoms such as feeling hungry shortly after eating substantial meals, experiencing energy crashes following carbohydrate-rich foods, or finding portion control particularly challenging
If your B12 levels are sufficient, you may not see an increase in energy
H3 GLP-1, or glucagon-like peptide 1, is a hormone naturally produced in the gut in response to eating
Interestingly, differences in prooxidative parameters were more profound in acute coronary syndrome patients compared with coronary artery disease patients indicating that the acute form of coronary artery disease is more susceptible to oxidative damage, suggesting that use of antioxidant therapy may be warranted to reduce oxidative stress in this disorder (154)
10.1074/mcp.M111.015248